PMID: 937Nov 1, 1975

Bone marrow transplantation in man

Annals of Internal Medicine
M J ClineJ Fahey

Abstract

Bone marrow transplantation is emerging as a viable therapeutic approach to a number of diseases that are usually or uniformly fatal. We review here recent experiences in bone marrow transplantation in man at UCLA and in various other institutions throughout the world. We examine marrow transplantation in immunodeficiency diseases, acute leukemia, and aplastic anemia and consider the problems of infection in the transplant recipients. The applications of tissue typing to marrow transplantation and immunologic manipulations, which may influence engraftment and graft-versus-host disease, are also reported.

Citations

Jan 1, 1978·American Journal of Hematology·P I LiuJ K Upshur
May 10, 1979·The New England Journal of Medicine·E L ReinherzS F Schlossman
Dec 1, 1976·Maryland State Medical Journal·G W Santos, P J Tutschka
Oct 1, 1977·Vox Sanguinis·M C SparkesS A Feig
Apr 1, 1978·Australian and New Zealand Journal of Medicine·J P IsbisterR Penny
Jul 1, 1978·Acta paediatrica Scandinavica·G PrindullN Meulen
Jan 1, 1983·Ophthalmology·R M FranklinG W Santos
Mar 1, 1976·International Journal of Radiation Oncology, Biology, Physics·R J MillerA S Tesler
Oct 1, 1980·Cryobiology·P I LiuL Crook
Apr 1, 1979·The American Journal of Medicine·P R Graze, R P Gale
Dec 1, 1976·British Journal of Haematology·H E Kay

Related Concepts

Blood Group H Type 1 Antigen
Acute Disease
Hypoplastic Anemia
Bone Marrow Cells
Cyclophosphamide, (S)-Isomer
Graft Vs Host Reaction
SD Antigens
HLA Typing
Immunologic Deficiency Syndromes
Therapeutic Immunosuppression

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.